SCHEMBL18786900

SCHEMBL18786900

COc1ccc(CN2C(=O)c3c(Cl)cc(Nc4cc(NC(=O)C5CC5)ncn4)cc3C23CCCCC3)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TUBB4A P04350 1/20 0.46
▸ TUBB P07437 1/20 0.46
▸ TUBA3C P0DPH7 1/20 0.46
▸ TUBA1B P68363 1/20 0.46
▸ TUBA4A P68366 1/20 0.46
▸ TUBB4B P68371 1/20 0.46
▸ TUBB3 Q13509 1/20 0.46
▸ TUBB2A Q13885 1/20 0.46
▸ TUBB8 Q3ZCM7 1/20 0.46
▸ TUBA3E Q6PEY2 1/20 0.46
▸ TUBA1A Q71U36 1/20 0.46
▸ TUBA1C Q9BQE3 1/20 0.46
▸ TUBB6 Q9BUF5 1/20 0.46
▸ TUBB2B Q9BVA1 1/20 0.46
▸ TUBB1 Q9H4B7 1/20 0.46
▸ MKNK2 Q9HBH9 5/20 0.43
▸ MKNK1 Q9BUB5 4/20 0.43
▸ EGFR P00533 4/20 0.41
▸ FGFR1 P11362 2/20 0.41
▸ ABL1 P00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18786917 0.90 GSK3B (0.38) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL18786716 0.89 TUBB4A (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL18786603 0.84 MKNK1 (0.40) MKNK2MKNK1EGFRLMNATSHR
SCHEMBL18786693 0.83 GSK3B (0.38) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL18786740 0.82 GSK3B (0.38) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL18786782 0.82 GSK3B (0.38) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL18786640 0.82 GSK3B (0.38) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL18787102 0.81 GSK3B (0.37) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL18786874 0.81 LMNA (0.41) LMNATP53POLBHPGDRAB9A
SCHEMBL18787027 0.80 KDR (0.37) LMNANPC1TP53POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190152988-A1 ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 EFFECTOR THERAPEUTICS, INC. (JP) 2019-05-23 — — US disclosed
US-10112955-B2 Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 EFFECTOR THERAPEUTICS, INC. (US) 2018-10-30 — — US disclosed
US-20170121346-A1 ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 OXFORD FINANCE LLC, AS COLLATERAL AGENT 2017-05-04 — — US disclosed
US-20170121346-A1 ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 OXFORD FINANCE LLC, AS COLLATERAL AGENT 2017-05-04 — — US disclosed
WO-2017075394-A1 ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 EFFECTOR THERAPEUTICS, INC. (US) 2017-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10112955-B2 Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 NEK9, NEK2, NEK3 TUBB4A 677/4885TUBB 814/4885TUBA3C 1186/4885
US-20190152988-A1 ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 NEK9, NEK2, NEK3 TUBB4A 677/4885TUBB 814/4885TUBA3C 1186/4885
US-20170121346-A1 ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 NEK9, NEK2, NEK3 TUBB4A 677/4885TUBB 814/4885TUBA3C 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback